IP Library Granted Patent US 7,696,309
Granted Patent B2
US 7,696,309 · App. 11/976,032 · Granted Apr 13, 2010

Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,696,309
App. No.
11/976,032
Granted
Apr 13, 2010
Kind
B2
Abstract

The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.

Claims (24)

1. An isolated mutant form of stromal cell derived factor-1 (SDF-1) peptide comprising a mutant SDF-1 (mSDF-1) or X p -mSDF-1, wherein:

a) X is proteinogenic amino acid(s) or a protease protective organic group;

b) p is any integer from 1 to 4;

c) said mSDF-1 comprises the amino acid sequence of SEQ ID NO:53, wherein mSDF-1 maintains chemoattractant activity for T cells and is inactivated by matrix metalloproteinase-2 (MMP-2) at a rate that is less than one-half of the rate of inactivation of native SDF-1; and

d) X p -mSDF-1 is a mutant form of said SDF-1 comprising the amino acid sequence of SEQ ID NO: 53, wherein Xe-mSDF-1 maintains chemoattractant activity for T cells, is inactivated by dipeptidyl peptidase IV (DPPIV) at a rate that is less than one-half of the rate at which native SDF-1 is inactivated, and is inactivated by MMP-2 at a rate that is less than one-half of the rate of inactivation of native SDF-1.

2. The isolated mutant SDF-1 peptide of claim 1 , wherein said mSDF-1 peptide or said X p -mSDF-1 peptide is SDF(S4V) consisting of SEQ ID NO:54.

3. An isolated mutant form of SDF-1 peptide comprising the mutant SDF-1 (mSDF-1) or X p -mSDF-1, wherein:

a) X is proteinogenic amino acid(s) or a protease protective organic group;

b) p is any integer from 1 to 4;

c) mSDF-1 is a mutant form of said SDF-1 comprising the amino acid sequence of SEQ ID NO:55, wherein mSDF-1 maintains chemoattractant activity for T cells and is inactivated by MMP-2 at a rate that is less than one-half of the rate of inactivation of native SDF-1; and

d) X p -mSDF-1 is a mutant form of said SDF-1 comprising the amino acid sequence of SEQ ID NO: 55, wherein X p -mSDF-1 maintains chemoattractant activity for T cells, is inactivated by DPPIV at a rate that is less than one-half of the rate at which native SDF-1 is inactivated, and is inactivated by MMP-2 at a rate that is less than one-half of the rate of inactivation of native SDF-1.

4. The isolated mutant SDF-1 peptide of claim 3 , wherein said mSDF-1 peptide or said Xp-mSDF-1 peptide is SDF(L5P) consisting of SEQ ID NO:56.

5. The isolated mutant SDF-1 peptide of claim 2 , wherein said isolated mutant SDF-1 peptide is an Xp-mSDF-1 peptide comprising the amino acid sequence of SEQ ID NO: 54, wherein X is a serine and p equals one.

6. A fusion protein comprising the formula: A-(L) n -(R) q , wherein: A is the isolated mutant SDF-1 peptide of any one of claims 2 - 5 , n is an integer from 0-3; q is an integer from 1-3; L is a linker sequence of 3-9 amino acids, and R is a self-assembling peptide as set forth in RARADADARARADADA (SEQ ID NO: 35).

7. The isolated mutant SDF-1 peptide of claim 1 , wherein said mSDF-1 peptide or said Xp-mSDF-1 peptide maintains chemoattractant activity for T cells of at least 10% that of native SDF-1 and is inactivated by MMP-2 at a rate that is less than one-fourth of the rate of inactivation of native SDF- 1.

8. The fusion protein of claim 6 , wherein n=1 and L is GGGGGG (SEQ ID NO:57).

9. The fusion protein of claim 8 , wherein A is the mSDF-1 peptide of SEQ ID NO:54.

10. The fusion protein of claim 9 , wherein q=1 and R is RARADADARARADADA (SEQ ID NO:35).

11. The fusion protein of claim 6 , wherein: A is an Xp-mSDF-1 peptide comprising the amino acid sequence of SEQ ID NO: 54, wherein X is a serine and p equals one; wherein n is an integer from 0-3; q=1; L is a linker sequence of 3-9 amino acids, and R is RARADADARARADADA (SEQ ID NO:35).

12. The fusion protein of claim 11 , wherein n=1 and L is GGGGGG (SEQ ID NO:57).

13. The fusion protein of claim 6 , wherein: A is an Xp-mSDF-1 peptide comprising the amino acid sequence of SEQ ID NO: 56, wherein X is a serine and p equals one; wherein n is an integer from 0-3; q=1; L is a linker sequence of 3-9 amino acids, and R is RARADADARARADADA (SEQ ID NO:35).

14. The fusion protein of claim 13 , wherein n=1 and L is GGGGGG (SEQ ID NO:57).

15. The isolated mutant SDF-1 peptide of claim 4 , wherein said isolated mutant SDF-1 peptide is an Xp-mSDF-1 peptide comprising the amino acid sequence of SEQ ID NO: 56, wherein X is a serine and p equals one.

16. The isolated mutant SDF-1 peptide of claim 9 , wherein said mSDF-1 peptide or said Xp-mSDF-1 peptide maintains chemoattractant activity for T cells of at least 10% that of native SDF-1 and is inactivated by MMP-2 at a rate that is less than one-fourth of the rate of inactivation of native SDF-1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2014
From: PROVASCULON, INC.
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 031895/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2007
From: LEE, RICHARD; SEGERS, VINCENT
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 020172/0512 →